Staphylococcus haemolyticus isolated from hospital patient resistance to antibiotics and resistance to antimicrobial genes

Abstract

Coagulase-negative staphylococci (CoNS) are normal inhabitants of human and animals. Staphylococcus haemolyticus is a member of the coagulase-negative staphylococci (CoNS). Among CoNS, S. haemolyticus is a common species encountered in the clinical samples, usually isolated from the axillae and glabrous skin of arms, legs and trunk of humans. Like other CoNS, S. haemolyticus does not usually cause human disease, but it is increasingly recognized as a potentially opportunistic and nosocomial pathogen and may occasionally cause infection in patients with abnormally weak immune systems. The aim of this stud y was to determine antimicrobial susceptibility and antimicrobial resistance profile of Staphylococcus haemolyticus isolated from hospital patient. Methods During 2014-2015 years 125 specimens were collected from patients with urinary tract infection. Isolation of staphylococci was performed using Mannitol Salt Agar and Plasmacoagulase test was performed as well. Species identification was performed using Microgen Staph ID (Microgen Bioproducts). Antimicrobial susceptibility was performed using “Sensititre” (Trek Diagnostic Systems) plates. Genes encoding resistance to separate classes of antimicrobials were detected by PCR. Interpretation of results was performed according to EUCAST recommendations. Results 57 (43.8%) samples from 130 tested were S. haemolyticus. 47 (84.2%) S. haemolyticus strains demonstrated resistance to one or more antibiotcs from 57 isolated. The resistance of 57 S. haemolyticus isolates was detected to penicillin (71.91%), oxacillin (59.4%), ampicillin (57.9%), erythromycin (86%), tetracycline (57.9%), trimethoprim/sulfamethoxazole (35.1%), ciprofloxacin (59.4%), clindamycin (31.6%), gatifloxacin (50.9%), levofloxacin (54.4%), gentamicin (45.6%). 34 (59.6%) isolated S. haemolyticus strains were resistant to methicillin, all strains were susceptible to vancomycin, quinupristin/ dalfop[...].